Online Journal for the Moose Pond Investors Club

Maxim Integ. Prod. (MXIM)

SSG and PERT | Google Stocks | Company Website

MXIM Logo

Maxim reported earnings for the fiscal year ending June 24, 2006. The company reported revenue growth of 11.2%. However, net income fell (-14.4%)and diluted EPS fell (14.9%) from $1.578 to $1.372. See Maxim’s press release. The expensing of stock based compensation contributed to the poor earnings.

Maxim and Linear Technologies (LLTC) are similar companies with different niches in the semiconducter industry. They had similar results this year, increased revenue growth but declining earnings. LLTC’s EPS did not decline as much as that of MXIM.

Should we sell MXIM? The short answer is no. The company’s fundamentals — the basis on which we buy or hold stocks — still look very good. On Friday, Maxim reported record-high quarterly revenue as bookings. The company has no long term debt. Net profit margins have remained strong. Value Line projects 20% sales growth and 15.5% earnings growth. The analysts consensus for 5-year earnings growth rate is 20%. Morningstar gives Maxim a 5-start rating (meaning it is priced well below fair value), a wide moat, and a stewardship grade of B. Manifest Investing rates its quality 69.

Whenever the earnings of a growth company falter, the price of the stock usually tumbles. Maxim’s stock price is near its three year low even though the company’s fundamentals and business model appear to be intact.

We currently hold 58 shares of Maxim valued at $2,090. It is 4.3% of our portfolio. Our average cost is $35.88 per share. The current share price is $27.94. We have a net loss of $462. (We also have a net loss for Intel, another semiconductor stock.) Revising the stock selection guide for a projected 15% EPS growth, projected average return is 21.5%. At his point, we probably have more to gain than lose by holding Maxim.
(more…)


Report for July 2006

In July, the Moose Pond Investors portfolio declined 0.13% while the S&P 500 increased 0.52%. Year to date, the portfolio declined 0.12% while the S&P increased 2.28%. The unit value of a share was $13.12 on July 31.

The biggest gainers in July were Pfizer (PFE) +10.8%, Stryker Corp. (SYK) +8.1%, and Brown & Co. (BRO) +7.4%. The biggest losers were Capital One Financial (COF) -9.5%, Maxim Integrated products (MXIM) -8.5%, and Factset Research (FDS) -7.2%.

The portfolio remains diversified with 25 holdings. The following chart from Morningstar compares the sector diversification of the portfolio with the S&P 500.  In adding to the portfolio, we should probably avoid further overweighting of the services sector. 

As the chart on the rights shows, the portfolio consists of large cap (57%), medium cap (38%), and  small cap (65%) stocks.  We should focus on finding more medium and small cap stocks.

Looking at style, the portfolio consist of value (18%), blend (35%), and growth (48%).  This mix is probably OK but growth stocks have taking quite a drubbing over the past 12 months.  (For a comparison of growth and value stock returns by year see the Callan Periodic Table.)


SSGs Updated

The stock selection guides (SSGs) for each of the stocks in the portfolio have been updated as of June 30. Follow the links in the portfolio summary for the current SSGs.

The PERT Chart and Trend Report also have been updated. The PERT chart is sorted by total return while the trend report is sorted by projected average return.


Mid-Year Report

Unit share price on June 30 was $13.14 up only slightly from the $13.09 at the beginning of the year. The IRR was 0.7%.  In comparison, the S&P 500 was up 1.76% for the same six month period.  (Actual gain for the S&P will be slightly higher with dividends.)

Top five advancers for the first half of 2006 were:  Occidental Petroleum, OXY (+29.4%), Investors Financial, IFIN (+20.2%), FactSet Research Systems, FDS (+15.2%), Chevron, CVX (11.1%), and Maxim Integrated products, MXIM (+5.0%).  The five biggest decliners for the same period were:  INTC (-20.2%), Amgen, AMGN (-17.6), Affiliated Computer Systems, ACS (-13.8), Marsh & McLennan Companies, MMC (-14.4), and Stryker, SYK (-8.0%).

With the possible exception of MMC, the fundamentals of the decliners remain intact and don’t warrant sale of these stocks.  The wide range reflected by the return of the top and bottom stocks for 2006 underscores the importance of diversification and adding regularly to the portfolio. 


June Transactions

On Wednesday, we added 18.8 shares of SNV and 23.9 shares of MXIM. We closed our positions in HDI (20.1 shares) and FITB (39.9 shares).  On Friday, we added 11.4 shares of JKHY, 9.8 shares of LOW, 12.1 shares of AMGN, and 10.3 shares of COF.

This reduces the number of companies in the portfolio to 24.  We only have 1.1% in cash.  UTSI jumped for $6.50 to $7.79 this week.  So maybe we should hold a while more.

Here is a dashboard for the portfolio reflecting these transactions.


Sold Fifth Third Bancorp

FactSet Research Systems, Inc. (FDS)
SSG and PERT A | Google Stocks | Company Website

Fifth Third BancorpWe sold Fifth Third Bancorp on June 28, 2006. FITB’s performance has been subpar for some time. It has also had a defection of senior management people. The proceeds from the sale have been redeployed to other financial stocks in our portfolio that have brighter prospects.
(more…)


Page 8 of 26« First...678910...20...Last »
Powered by WordPress | Designed by Elegant Themes